SynthesisOrphanet journal of rare diseases2019

Agreement between results of meta-analyses from case reports and clinical studies, regarding efficacy and safety of idursulfase therapy in patients with mucopolysaccharidosis type II (MPS-II). A new tool for evidence-based medicine in rare diseases.

Miguel Sampayo-Cordero et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.